{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:08:52Z","timestamp":1783526932323,"version":"3.55.0"},"reference-count":15,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JBM"],"DOI":"10.2147\/jbm.s507550","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:55:07Z","timestamp":1747148107000},"page":"233-239","source":"Crossref","is-referenced-by-count":7,"title":["Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed\/Refractory Multiple Myeloma: Updated Results"],"prefix":"10.2147","volume":"Volume 16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6366-9178","authenticated-orcid":true,"given":"Isha","family":"Mol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"LeBlanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9586-0748","authenticated-orcid":true,"given":"Joseph","family":"Cappelleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Nador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didem","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Perez Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hlavacek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41375-021-01471-3","volume":"36","author":"Bal","year":"2022","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nature Medicine"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"Moreau","year":"2022","journal-title":"New England Journal of Medicine"},{"key":"ref6","unstructured":"United States Food and Drug Administration. Highlights of prescribing information. ELREXFIO\u2122 (elranatamab-bcmm) injection, for subcutaneous use. Initial U.S. Approval: 2023. 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761345s000lbl.pdf. Accessed April 16, 2025."},{"key":"ref7","unstructured":"United States Food and Drug Administration. Highlights of prescribing information. TECVAYLI\u2122 (teclistamab-cqyv) injection, for subcutaneous use. Initial U.S. Approval: 2022; 2024. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761291s000lbl.pdf. Accessed April 16, 2025."},{"key":"ref8","unstructured":"European Medicines Agency. Tecvayli (teclistamab). An overview of Tecvayli and why it is authorised in the EU; 2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/tecvayli-epar-medicine-overview_en.pdf. Accessed April 16, 2025."},{"key":"ref9","unstructured":"European Medicines Agency. Elrexfio (elranatamab). An overview of Elrexfio and why it is authorised in the EU; 2024."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1080\/10428194.2024.2313628","volume":"65","author":"Mol","year":"2024","journal-title":"Leukemia & Lymphoma"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","volume":"42","author":"Garfall","year":"2024","journal-title":"Journal of Clinical Oncology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1002\/hem3.136","volume":"8","author":"Tomasson","year":"2024","journal-title":"HemaSphere"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"ref14","unstructured":"Phillippo D, Ades T, Dias S, Palmer S, Abrams KR, Welton N NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE; 2024. Available from: https:\/\/research-information.bris.ac.uk\/ws\/portalfiles\/portal\/94868463\/Population_adjustment_TSD_FINAL.pdf. Accessed April 16, 2025."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989x17725740","volume":"38","author":"Phillippo","year":"2018","journal-title":"Med Decis Making"}],"container-title":["Journal of Blood Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/102923","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/102923","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:55:11Z","timestamp":1747148111000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/matching-adjusted-indirect-comparison-of-elranatamab-versus-teclistama-peer-reviewed-fulltext-article-JBM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":15,"URL":"https:\/\/doi.org\/10.2147\/jbm.s507550","relation":{},"ISSN":["1179-2736"],"issn-type":[{"value":"1179-2736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}